Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853120 · ClinicalTrials.gov registry record · Phase 4
Doxy-Post-exposure Prophylaxis
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT05853120 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 45 participants.
The verdict
NCT05853120, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The goal of this project is to collect data regarding the ability of various oral doses of doxycycline to penetrate mucosal tissues in men and women to inform the combination of doxycycline with antiretrovirals (ARVs) for the development of single-dose event-driven multipurpose prevention strategies to protect against HIV and sexually transmitted infections (STIs). This study is of importance in the field of research because it allows the exploration of new dosing strategies that would permit a single event-driven oral dose of medications that could provide protection from HIV as well as other STIs. The study population that this study seeks to enroll are healthy people assigned male or female sex at birth and not using gender-affirming hormone therapy and are willing to undergo study procedures. Recruitment: Both face-to-face and online engagements will be conducted to recruit study participants. Face-to-face locations include bars and nightclubs, community organizations serving study populations, sports events, and community venues, and online engagements include dating sites, social networks, and craigslist, amongst other social medial platforms.
Interventions
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2024-12-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05853120
The ClinicalTrials.gov registry entry for NCT05853120 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxycycline is the first listed.
NCT05853120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05853120 about?
NCT05853120 is a clinical study titled "Doxy-Post-exposure Prophylaxis". The goal of this project is to collect data regarding the ability of various oral doses of doxycycline to penetrate mucosal tissues in men and women to inform the combination of doxycycline with antiretrovirals (ARVs) for the development of single-dose event-driven multipurpose prevention strategies...
What is the current status of trial NCT05853120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2023-05-31. Estimated completion is 2024-12-24.
What interventions are being tested in trial NCT05853120?
The interventions under investigation include: Doxycycline (DRUG).
Who is sponsoring clinical trial NCT05853120?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.